Boehringer Ingelheim GmbH has set an ambitious goal of up to 15 new product launches through 2025 backed by a €4.1bn R&D spend in 2021, nearly 12% up on the previous year and the highest investment in the 137-year history of the German family-owned company.
Late-Stage Pipeline Blooming At Boehringer As R&D Spend Soars
Jardiance And Ofev Sales Continue To Climb
Over the next five years, the German group is looking to invest over €25bn in the R&D pipeline, with oncology a key focus.
More from Earnings
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.